1973. 66. Royal College of General Practitioners: Oral contraceptives and health. New York – Newsemia

1973. 66. Royal College of General Practitioners: Oral contraceptives and health. New York

NECON (Norethindrone And Mestranol) Kit [Actavis Pharma, Inc.]

July 24, 2018
0
Category:
- Pharma / Biotech
Tags: [t 1. Trussell J. Contraceptive Efficacy Table from Hatcher R.A.1966. 73. Fisch 1968. 27. Maguire 1968. 30. Vessey 1969. 31. Porter 1970. 37. Meade 1973. 66. Royal College of General Practitioners: Oral contraceptives and health. New York 1974. 67. Rome Group for the Epidemiology and Prevention of Cholelithiasis: Am J Epidemiol 119(5):796–805 1974. 9. Ory 1975. 16. Royal College of General Practitioners’ Oral Contraceptive Study: Lancet 1:541–546 1975. 3. Knopp 1975. 36. Inman 1976. 10. Ory 1976. 33. Mishell 1976. 5. Ory 1976. 51. Vessey 1976. 75. Ramcharan 1976. 77. Dickey 1977. 40. Royal College of General Practitioners’ Oral Contraception Study: J Coll Gen Pract 33:75–82 1977. 56. Klatskin 1977. 57. Henderson 1977. 6. The Cancer and Steroid Hormone Study of the Centers for Disease Control: JAMA 249(2):1596–1599 1977. 74. Laragh 1977. 76. Stockley 1977.Close 1978. 35. Collaborative Group for the Study of Stroke in Young Women: JAMA 231(7):718–722 1978. 84. Royal College of General Practitioners’ Oral Contraception Study: Effect on Hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1:624 1979. 28. Petitti 1979. 29. Vessey 1979. 34. Petitti 1979. 55. Bein 1979. 65. Boston Collaborative Drug Surveillance Program: Lancet 1:1399–1404 1979. 71. Wynn 1980. 19. Russell-Briefel 1980. 38. Kay 1980. 61. Savolainen 1980. 63. Ferencz 1980. 64. Rothman 1981. 13. Stadel 1981. 14. Adam 1981. 15. Mann 1981. 17. Slone 1981. 18. Vessey 1981. 62. Janerich 1982. 11. Ory 1982. 25. Wynn V.1982. 32. Vessey 1982. 39. Gordon 1983. 12. Stadel 1983. 23. Wahl 1983. 41. Ory 1983. 42. Paul 1983. 45. Miller 1983. 52. Brinton 1983. 58. Neuberger 1983. 7. The Cancer and Steroid Hormone Study of the Centers for Disease Control: JAMA 257(6):796–800 1983. 72. Wynn 1984. 68. Strom 1984. 78. Porter J.B.1985. 47. McPherson 1985. 54. Rooks 1985. 70. Wynn 1986. 20. Goldbaum 1986. 22. Krauss 1986. 26. Inman 1986. 4. Mann 1986. 43. The Cancer and Steroid Hormone Study of the Centers for Disease Control: N Engl J Med 315(7):405–411 1986. 44. Pike 1986. 46. Olsson 1986. 50. Ory 1986. 53. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Br Med J 290:961–965 1986. 59. Forman 1986. 60. Harlap 1986. 69. Perlman 1987. 21. LaRosa 1987. 48. Huggins 1987. 49. McPherson 1987. 8. Ory 1989. 81. Schlesselman J.1998. 2. Mann and varicose veins. J Coll Gen Pract 28:393–399 B.: N Engl J Med 305(11):612–618 B.: N Engl J Med 305(12):672–677 B.E.B.L.Bain C.Belanger C.C.R.: Am J Obstet Gynecol 142(6):762–765 c)Cates W Creative Informatics Inc.d D. B.D.R.D.T.e et al.: Am J Epidemiol 109(4):433–439 et al.: Am J Epidemiol 110(2):188–195 et al.: Am J Epidemiol 112(1):73–79 et al.: Am J Med 62:707–714 et al.: Am J Obstet Gynecol 124(6):573–577 et al.: Am J Obstet Gynecol 140(5):521–524 et al.: Am J Obstet Gynecol 142(6):766–771 et al.: Am J Obstet Gynecol 145:446–452 et al.: Br J Cancer 48:437–440 et al.: Br J Cancer 56:653–660 et al.: Br J Obstet Gynaecol 88:838–845 et al.: Br J Surg 64:433–435 et al.: Br Med J 2:203–209 et al.: Br Med J 2:445–447 et al.: Br Med J 2(5599):193–199 et al.: Br Med J 2(5599):199–205 et al.: Br Med J 2(5658):651–657 et al.: Br Med J 2(5956):241–245 et al.: Br Med J 2(5965):245–248 et al.: Br Med J 280(6224):1157–1161 et al.: Br Med J 292:1355–1357 et al.: Br Med J 292:1357–1361 et al.: Br Med J 293:709–710 et al.: Br Med J 293:723–725 et al.: Clin Pharmacol Ther 39(3):335–341 et al.: Fertil Steril 47(5):733–761 et al.: Int J Cancer 38:339–344 et al.: J Biosoc Sci 8:373–427 et al.: J Chronic Dis 38(10):857–864 et al.: J Reprod Med 31(9):892–897 et al.: JAMA 237(23):2499–2503 et al.: JAMA 242(11):1150–1154 et al.: JAMA 242(7):644–648 et al.: JAMA 258(10):1339–1342 et al.: Lancet 1:1045–1049 et al.: Lancet 2:234–236 et al.: Lancet 2:720–723 et al.: Lancet 2:748–749 et al.: Lancet 2:926–929 et al.: Lancet 2:930 et al.: Making Choices et al.: N Engl J Med 294:419–422 et al.: N Engl J Med 305(8):420–424 et al.: N Engl J Med 308(15):862–867. 1983. 24. Wynn et al.: Obstet Gynecol 1985;66:1–4. 79. Porter J.B.et al.: Obstet Gynecol 55(4):447–452 et al.: Obstet Gynecol 59(3):299–302 et al.: Obstet Gynecol 68:863–868 et al.: Pharmacology of Steroid Contraceptive Drugs et al.: Prev Med 5:352–362 et al.: Reproductive Endocrinology et al.: Teratology 21:225–239 F.A. Davis Co.F.D.A.g G.: Gastroenterology 73:386–394 G.R.Guest F h H.: JAMA 237:2619–2622 H.W.H.W.: Fam Plann Perspect 14:182–184 H.W.: Fam Plann Perspect 15(2):57–63 H.W.: JAMA 228(1):68–69 Hershel J.Hunter J.I.: Pharm J 216:140–143 I.R.in Contraceptive Technology: Seventeenth Revised Edition. New York J.J.A.J.B.J.C.: J Reprod Med 31 (9):906–912 J.H.: Am J Obstet Gynecol 126(1):141–147 J.I.Jick H.K.K. J.Kowal D L.A.Lai S.: Breast cancer in relation to early use of oral contraceptives. JAMA 1988;259:1828–1833. 82. Hennekens C.H.Lipnick R.J.M. P.M.C.M.G.M.P.: Br J Fam Plann 6 (Supplement): 1–12 Murray P.N.N.new york NY: Irvington Publishers October Oklahoma p Peto R.: A case-control study of oral contraceptive use and breast cancer. JNCI 1984;72:39–42. 83. Royal College of General Practitioners: Oral contraceptives Philadelphia Pittman r R. M.R.H.: J Reprod Med 31(9):913–921 R.P.: Managing Contraceptive Pill Patients Raven Press Rosner B.s Speizer F.E.Stadel B.V.Stampfer M.J.Stewart F Stewart GK T.W.The Alan Guttmacher Institute Trussell J V.V.: Progesterone and Progestin venous thrombosis W.H.Walker A.M.: Obstet Gynecol 1987;70:29–32. 80. Fertility and Maternal Health Drugs Advisory Committee Willett W.

Updated Date: Jul 24, 2018 EST

Read more